Back to News
Mar 19, 2026 4:10 AM

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.

SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term success across multiple modalities. The company continues to expand its small molecule and peptide businesses while reinforcing its commitment to viral vector development and manufacturing, and believes this three-business-unit approach positions SK pharmteco as a versatile CDMO partner for biopharma companies managing increasingly diverse pipelines, from established therapeutics to advanced therapies.

To advance this strategy, $100 million USD will be deployed ...